Pharvaris Presents Positive Phase 2 Data from RAPIDe-1 Study of PHVS416
- ByInvesting.com-
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today...